Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
KAT6A is a histone acetyltransferase involved in transcriptional co-activation, proliferation and differentiation of hematopoietic progenitor and stem cells. Mutations and translocations in KAT6A are oncogenic drivers in hematological malignancies.
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.
Blueprint Medicines Corp. has synthesized EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer.
Shenzhen Maxinovel Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety covalently bonded to a Wee1-like protein kinase (Wee1)-targeting moiety through a linker.
Engine Biosciences Pte. Ltd. has completed a $27 million series A extension to support the progression of the company’s biomarker and target discoveries toward the clinic through internal development, collaborations and partnerships.
Researchers from Taisho Pharmaceutical Co. Ltd. have discovered new heparanase-1 (HPSE1) inhibitors for the treatment of cancer and proteinuric kidney diseases.
Researchers from Medigene AG recently presented the discovery and preclinical evaluation of first-in-class, third-generation T-cell receptor T-cell (TCR-T) therapies, MDG-1015 and MDG-2011.
RSS
